BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23171135)

  • 21. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
    Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
    J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
    Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
    Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
    Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
    Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
    Yoshimoto M; Cunha IW; Coudry RA; Fonseca FP; Torres CH; Soares FA; Squire JA
    Br J Cancer; 2007 Sep; 97(5):678-85. PubMed ID: 17700571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.
    Lin HK; Hu YC; Lee DK; Chang C
    Mol Endocrinol; 2004 Oct; 18(10):2409-23. PubMed ID: 15205473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.
    Callen DF; Ricciardelli C; Butler M; Stapleton A; Stahl J; Kench JG; Horsfall DJ; Tilley WD; Schulz R; Nesland JM; Neilsen PM; Kumar R; Holm R
    Oncol Rep; 2010 Apr; 23(4):1045-52. PubMed ID: 20204290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
    Ford OH; Gregory CW; Kim D; Smitherman AB; Mohler JL
    J Urol; 2003 Nov; 170(5):1817-21. PubMed ID: 14532783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
    Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
    Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
    Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
    Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naïve Prostate Cancer.
    Poelaert F; Kumps C; Lumen N; Verschuere S; Libbrecht L; Praet M; Rottey S; Claeys T; Ost P; Decaestecker K; De Meerleer G; Van Praet C
    Urol Int; 2017; 99(2):222-228. PubMed ID: 28052297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.
    Liu AJ; Furusato B; Ravindranath L; Chen YM; Srikantan V; McLeod DG; Petrovics G; Srivastava S
    J Zhejiang Univ Sci B; 2007 Dec; 8(12):853-9. PubMed ID: 18257117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.
    Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA
    Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer.
    Pardy L; Rosati R; Soave C; Huang Y; Kim S; Ratnam M
    Prostate; 2020 Feb; 80(2):198-208. PubMed ID: 31794091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer.
    Alioui A; Dufour J; Leoni V; Loregger A; Moeton M; Iuliano L; Zerbinati C; Septier A; Val P; Fouache A; Russo V; Volle DH; Lobaccaro JA; Zelcer N; Baron S
    Nat Commun; 2017 Sep; 8(1):445. PubMed ID: 28874658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
    Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
    Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.